<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03324061</url>
  </required_header>
  <id_info>
    <org_study_id>EGL-5835-C-1701</org_study_id>
    <nct_id>NCT03324061</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety, Tolerability, and PK of Fulvestrant After IM Administration</brief_title>
  <official_title>A Phase 1, Randomized, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Fulvestrant (Test vs. Reference) Following Intramuscular Administration to the Gluteal Muscle in Healthy Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eagle Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eagle Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical study designed to assess the plasma pharmacokinetic profile and tolerability of&#xD;
      Fulvestrant for Injectable Suspension after a single IM dose of Fulvestrant for Injectable&#xD;
      Suspension compared to the reference product, Faslodex in healthy female subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1, open-label, parallel group study in healthy female subjects. The study is&#xD;
      designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of a single dose of&#xD;
      Fulvestrant for Injectable Suspension vs. the reference drug, Faslodex, administered in the&#xD;
      gluteal muscle.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 30, 2017</start_date>
  <completion_date type="Actual">July 12, 2018</completion_date>
  <primary_completion_date type="Actual">July 12, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic parameters</measure>
    <time_frame>Day 0 through Day 140</time_frame>
    <description>Area under the concentration-time curve(AUC)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">600</enrollment>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>Fulvestrant for Injectable Suspension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fulvestrant for Injectable Suspension (500 mg/vial)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Faslodex (R)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Faslodex (250 mg/mL)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant for Injectable Suspension</intervention_name>
    <description>Test drug is administered as a single 5mL intramuscular injection in the right or left dorsogluteal muscle area</description>
    <arm_group_label>Fulvestrant for Injectable Suspension</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Faslodex (Reference)</intervention_name>
    <description>Reference drug is administered as two 5mL intramuscular injections, one in each of the right and left dorsogluteal muscle areas</description>
    <arm_group_label>Faslodex (R)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body Mass Index (BMI) of 18 kg/m2 to 32 kg/m2&#xD;
&#xD;
          -  Body weight of at least 50 kg at screening&#xD;
&#xD;
          -  Good health as determined by evaluations&#xD;
&#xD;
          -  Negative serum pregnancy test&#xD;
&#xD;
          -  Subjects who are naturally postmenopausal for at least 12 consecutive months with a&#xD;
             follicle-stimulating hormone level at Screening of â‰¥40 mIU/mL&#xD;
&#xD;
          -  Subjects who are peri-menopausal and experiencing at least one of specified symptoms&#xD;
             of menopause (eg, hot flashes, mood swings, night sweats, and others)&#xD;
&#xD;
          -  Negative urine test for drugs of abuse&#xD;
&#xD;
          -  Negative urine test for HIV antibody, HBsAG, and HCV at Screening&#xD;
&#xD;
          -  Women of child-bearing potential must agree to consistently practice contraception&#xD;
             throughout the duration of the study and continue to do so for 1 year after receiving&#xD;
             study drug by one of the following methods: abstinence, condom, diaphragm or cervical&#xD;
             cap with spermicide, intrauterine device or male partner had previously undergone a&#xD;
             vasectomy as declared in medical history&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Recent history (6 months) or current evidence of any clinically significant&#xD;
             (uncontrolled) disorder including hepatic, renal, cardiovascular, psychological,&#xD;
             pulmonary, metabolic, endocrine, neurologic, infectious, gastrointestinal, hematologic&#xD;
             or oncologic disease, or other medical conditions that may interfere with the subject&#xD;
             completing the study&#xD;
&#xD;
          -  Lab test results outside the normal range at Screening or Day 1 considered clinically&#xD;
             significant by the Investigator&#xD;
&#xD;
          -  Use of hormonal replacement therapy within 6 months prior to randomization an/or&#xD;
             current use of oral contraceptive pill or patch as contraceptive method throughout the&#xD;
             study&#xD;
&#xD;
          -  Concomitant medication that can affect bleeding&#xD;
&#xD;
          -  Recent history (6 months) or presence of an abnormal ECG that, in the opinion of the&#xD;
             Investigator, is clinically significant&#xD;
&#xD;
          -  Subjects with QTcF interval duration &gt;470 milliseconds&#xD;
&#xD;
          -  History of alcoholism or drug addiction within 1 year prior to Day 1&#xD;
&#xD;
          -  History of allergy or a known sensitivity to product components of fulvestrant Test&#xD;
             and Reference formulations&#xD;
&#xD;
          -  Creatinine clearance &lt;60 mL/minute based on the Cockcroft-Gault equation&#xD;
&#xD;
          -  Blood donation of 500 mL or more or a significant loss of blood within 56 days prior&#xD;
             to Day 1&#xD;
&#xD;
          -  Previous exposure to fulvestrant&#xD;
&#xD;
          -  Familial relationship with another study participant&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrian J Hepner, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Eagle Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Collaborative Neuroscience Network, LLC</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Avail Clinical Research, LLC</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Pharmacology of Miami, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quotient Sciences</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Pharma CR, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33147</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Consortium</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hassman Research Institute</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Horizon Clinical Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Orleans Center for Clinical Research</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optimal Research, LLC</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Worldwide Clinical Trials</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 24, 2017</study_first_submitted>
  <study_first_submitted_qc>October 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2017</study_first_posted>
  <last_update_submitted>June 2, 2021</last_update_submitted>
  <last_update_submitted_qc>June 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fulvestrant</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

